ALSO NOTED: Inspire files amended NDA; Genetic variations influence Coumadin use; Immunomedics begins Phase III;and much more..

> Inspire Pharmaceuticals is taking another shot at gaining approval for its experimental treatment for dry eye, filing an amended NDA for a drug that has failed two Phase III trials. Story

> Newly discovered genetic variations play a role in determining the right dose of the anti-clotting drug Coumadin. Article

> Immunomedics of Morris Plains, New Jersey, has begun dosing patients in a Phase III trial of its lead drug -- epratuzumab -- for lupus. Release

> Teva Pharmaceutical has received final FDA approval for a generic version of Abbott's antibiotic Biaxin Tablets. Story

> Neurion Pharmaceuticals has won a $500,000 grant from the National Institute of Mental Health. Release

> Chiron and the Multiple Myeloma Research Consortium announced the initiation of a Phase I clinical trial of CHIR-258 in multiple myeloma. Release

And Finally... A variety of cash-strapped states are considering new "botaxes," adding levies on cosmetic procedures. Story

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.